• Something wrong with this record ?

ARB a diastolická funkce
[Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial]

Solomon SD, et al.

. 2007 ; 1 (5) : 37.

Language Czech Country Czech Republic

Diastolic dysfunction might represent an important pathophysiological intermediate between hypertension and heart failure. Our aim was to determine whether inhibitors of the renin-angiotensin-aldosterone system, which can reduce ventricular hypertrophy and myocardial fibrosis, can improve diastolic function to a greater extent than can other antihypertensive agents. METHODS: Patients with hypertension and evidence of diastolic dysfunction were randomly assigned to receive either the angiotensin receptor blocker valsartan (titrated to 320 mg once daily) or matched placebo. Patients in both groups also received concomitant antihypertensive agents that did not inhibit the renin-angiotensin system to reach targets of under 135 mm Hg systolic blood pressure and under 80 mm Hg diastolic blood pressure. The primary endpoint was change in diastolic relaxation velocity between baseline and 38 weeks as determined by tissue doppler imaging. Analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00170924. FINDINGS: 186 patients were randomly assigned to receive valsartan; 198 were randomly assigned to receive placebo. 43 patients were lost to follow-up or discontinued the assigned intervention. Over 38 weeks, there was a 12.8 (SD 17.2)/7.1 (9.9) mm Hg reduction in blood pressure in the valsartan group and a 9.7 (17.0)/5.5 (10.2) mm Hg reduction in the placebo group. The difference in blood pressure reduction between the two groups was not significant. Diastolic relaxation velocity increased by 0.60 (SD 1.4) cm/s from baseline in the valsartan group (p<0.0001) and 0.44 (1.4) cm/s from baseline in the placebo group (p<0.0001) by week 38. However, there was no significant difference in the change in diastolic relaxation velocity between the groups (p=0.29). INTERPRETATION: Lowering blood pressure improves diastolic function irrespective of the type of antihypertensive agent used.

Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial

000      
04341naa 2200481 a 4500
001      
bmc07506121
003      
CZ-PrNML
005      
20191213094342.0
008      
080630s2007 xr e cze||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a cze $b eng
044    __
$a xr
100    1_
$a Solomon, Scott D. $7 xx0243096
245    10
$a ARB a diastolická funkce / $c Solomon SD, et al.
246    11
$a Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial
314    __
$a Cardiovascular Division, Brigham and Women's Hospital, Boston
520    9_
$a Diastolic dysfunction might represent an important pathophysiological intermediate between hypertension and heart failure. Our aim was to determine whether inhibitors of the renin-angiotensin-aldosterone system, which can reduce ventricular hypertrophy and myocardial fibrosis, can improve diastolic function to a greater extent than can other antihypertensive agents. METHODS: Patients with hypertension and evidence of diastolic dysfunction were randomly assigned to receive either the angiotensin receptor blocker valsartan (titrated to 320 mg once daily) or matched placebo. Patients in both groups also received concomitant antihypertensive agents that did not inhibit the renin-angiotensin system to reach targets of under 135 mm Hg systolic blood pressure and under 80 mm Hg diastolic blood pressure. The primary endpoint was change in diastolic relaxation velocity between baseline and 38 weeks as determined by tissue doppler imaging. Analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00170924. FINDINGS: 186 patients were randomly assigned to receive valsartan; 198 were randomly assigned to receive placebo. 43 patients were lost to follow-up or discontinued the assigned intervention. Over 38 weeks, there was a 12.8 (SD 17.2)/7.1 (9.9) mm Hg reduction in blood pressure in the valsartan group and a 9.7 (17.0)/5.5 (10.2) mm Hg reduction in the placebo group. The difference in blood pressure reduction between the two groups was not significant. Diastolic relaxation velocity increased by 0.60 (SD 1.4) cm/s from baseline in the valsartan group (p<0.0001) and 0.44 (1.4) cm/s from baseline in the placebo group (p<0.0001) by week 38. However, there was no significant difference in the change in diastolic relaxation velocity between the groups (p=0.29). INTERPRETATION: Lowering blood pressure improves diastolic function irrespective of the type of antihypertensive agent used.
650    _2
$a senioři $7 D000368
650    _2
$a blokátory receptorů AT1 pro angiotensin II $x farmakologie $x škodlivé účinky $x terapeutické užití $7 D047228
650    _2
$a antihypertenziva $x farmakologie $x škodlivé účinky $x terapeutické užití $7 D000959
650    _2
$a krevní tlak $x účinky záření $7 D001794
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a echokardiografie $7 D004452
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a srdeční frekvence $x účinky léků $7 D006339
650    _2
$a lidé $7 D006801
650    _2
$a hypertenze $x farmakoterapie $x komplikace $7 D006973
650    _2
$a hypertrofie levé komory srdeční $x etiologie $x prevence a kontrola $7 D017379
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a renin-angiotensin systém $x účinky léků $7 D012084
650    _2
$a tepový objem $x účinky léků $7 D013318
650    _2
$a tetrazoly $x farmakologie $x škodlivé účinky $x terapeutické užití $7 D013777
650    _2
$a valin $x analogy a deriváty $x farmakologie $x terapeutické užití $x účinky léků $7 D014633
773    0_
$w MED00012706 $t Clinical cardiology alert $g Roč. 1, č. 5 (2007), s. 37 $x 1213-2586
910    __
$a ABA008 $b B 2242 $c 407 a $y 1 $z 0
990    __
$a 20080630105116 $b ABA008
991    __
$a 20191213094643 $b ABA008
999    __
$a ok $b bmc $g 621745 $s 474178
BAS    __
$a 3
BMC    __
$a 2007 $b 1 $c 5 $d 37 $i 1213-2586 $m Clinical Cardiology Alert $x MED00012706
LZP    __
$a 2008-6/mkme

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...